Predictors of survival in univariable and multivariable analysis
| . | Absolute Counts* . | Univariable Analysis . | Multivariable Analysis† . | |||||
|---|---|---|---|---|---|---|---|---|
| N1 (n1) . | N2 (n2) . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| TE during follow-up | 151 (20) | 30 (10) | 8.76 | 3.46-22.16 | <.001 | 5.95 | 2.43-14.59 | <.001 |
| Arterial TE | 151 (20) | 14 (7) | 10.55 | 4.07-27.33 | <.001 | 5.70 | 2.22-14.64 | <.001 |
| Venous TE | 151 (20) | 16 (3) | 2.58 | 0.73-9.15 | .14 | 2.82 | 0.81-9.82 | .10 |
| Age at study inclusion | 151 (20) | N/A | 1.06 | 1.04-1.09 | <.001 | 1.06 | 1.02-1.09 | .001 |
| Hypertension at study inclusion | 151 (20) | 44 (14) | 6.01 | 2.37-15.21 | <.001 | 3.29 | 1.13-9.60 | .03 |
| Diabetes at study inclusion | 151 (20) | 10 (6) | 7.21 | 2.75-18.93 | <.001 | 1.35 | 0.43-4.25 | .61 |
| Female sex | 151 (20) | 123 (16) | 0.92 | 0.31-2.75 | .88 | 0.48 | 0.15-1.55 | .22 |
| History of thrombosis | ||||||||
| Arterial TE | 151 (20) | 21 (4) | 1.49 | 0.50-4.47 | .47 | 0.97 | 0.30-3.18 | .96 |
| Venous TE | 151 (20) | 85 (9) | 0.67 | 0.28-1.62 | .37 | 1.60 | 0.64-3.97 | .31 |
| Arterial TE and/or venous TE | 151 (20) | 99 (12) | 0.82 | 0.32-1.95 | .62 | 1.35 | 0.50-3.60 | .55 |
| Pregnancy complications‡ | 95 (12) | 40 (3) | 0.44 | 0.12-1.62 | .22 | 8.85 | 0.87-90.04 | .07 |
| VKA at baseline | 151 (20) | 71 (9) | 0.95 | 0.39-2.30 | .91 | 1.61 | 0.63-4.09 | .32 |
| ARD at baseline | ||||||||
| SLE or LLD | 151 (20) | 48 (6) | 0.86 | 0.33-2.24 | .76 | 1.04 | 0.39-2.81 | .93 |
| SLE | 151 (20) | 29 (3) | 0.79 | 0.23-2.70 | .71 | 1.22 | 0.32-4.66 | .77 |
| LLD | 151 (20) | 19 (3) | 1.00 | 0.29-3.42 | .99 | 0.91 | 0.26-3.19 | .88 |
| aPLAs§ | ||||||||
| LA alone | 149 (20) | 42 (8) | 1.67 | 0.68-4.08 | .26 | 1.49 | 0.60-3.71 | .39 |
| LA + anti-β2GPI IgG/IgM | 149 (20) | 106 (12) | 0.64 | 0.26-1.56 | .32 | 0.70 | 0.28-1.76 | .46 |
| LA + anti-β2GPI IgG | 150 (20) | 83 (5) | 0.27 | 0.10-0.74 | .01 | 0.65 | 0.22-1.96 | .45 |
| LA + anti-β2GPI IgM | 149 (20) | 61 (10) | 1.41 | 0.59-3.39 | .44 | 1.17 | 0.47-2.92 | .74 |
| LA + aCL IgG/IgM | 151 (20) | 68 (6) | 0.48 | 0.18-1.26 | .14 | 0.76 | 0.27-2.17 | .61 |
| LA + aCL IgG | 151 (20) | 56 (4) | 0.35 | 0.12-1.05 | .06 | 0.68 | 0.21-2.21 | .52 |
| LA + aCL IgM | 151 (20) | 21 (3) | 1.22 | 0.36-4.15 | .76 | 1.29 | 0.36-4.64 | .69 |
| LA + anti-β2GPI + aCL (triple positivity) | 149 (20) | 66 (6) | 0.51 | 0.19-1.32 | .17 | 0.81 | 0.28-2.32 | .70 |
| . | Absolute Counts* . | Univariable Analysis . | Multivariable Analysis† . | |||||
|---|---|---|---|---|---|---|---|---|
| N1 (n1) . | N2 (n2) . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| TE during follow-up | 151 (20) | 30 (10) | 8.76 | 3.46-22.16 | <.001 | 5.95 | 2.43-14.59 | <.001 |
| Arterial TE | 151 (20) | 14 (7) | 10.55 | 4.07-27.33 | <.001 | 5.70 | 2.22-14.64 | <.001 |
| Venous TE | 151 (20) | 16 (3) | 2.58 | 0.73-9.15 | .14 | 2.82 | 0.81-9.82 | .10 |
| Age at study inclusion | 151 (20) | N/A | 1.06 | 1.04-1.09 | <.001 | 1.06 | 1.02-1.09 | .001 |
| Hypertension at study inclusion | 151 (20) | 44 (14) | 6.01 | 2.37-15.21 | <.001 | 3.29 | 1.13-9.60 | .03 |
| Diabetes at study inclusion | 151 (20) | 10 (6) | 7.21 | 2.75-18.93 | <.001 | 1.35 | 0.43-4.25 | .61 |
| Female sex | 151 (20) | 123 (16) | 0.92 | 0.31-2.75 | .88 | 0.48 | 0.15-1.55 | .22 |
| History of thrombosis | ||||||||
| Arterial TE | 151 (20) | 21 (4) | 1.49 | 0.50-4.47 | .47 | 0.97 | 0.30-3.18 | .96 |
| Venous TE | 151 (20) | 85 (9) | 0.67 | 0.28-1.62 | .37 | 1.60 | 0.64-3.97 | .31 |
| Arterial TE and/or venous TE | 151 (20) | 99 (12) | 0.82 | 0.32-1.95 | .62 | 1.35 | 0.50-3.60 | .55 |
| Pregnancy complications‡ | 95 (12) | 40 (3) | 0.44 | 0.12-1.62 | .22 | 8.85 | 0.87-90.04 | .07 |
| VKA at baseline | 151 (20) | 71 (9) | 0.95 | 0.39-2.30 | .91 | 1.61 | 0.63-4.09 | .32 |
| ARD at baseline | ||||||||
| SLE or LLD | 151 (20) | 48 (6) | 0.86 | 0.33-2.24 | .76 | 1.04 | 0.39-2.81 | .93 |
| SLE | 151 (20) | 29 (3) | 0.79 | 0.23-2.70 | .71 | 1.22 | 0.32-4.66 | .77 |
| LLD | 151 (20) | 19 (3) | 1.00 | 0.29-3.42 | .99 | 0.91 | 0.26-3.19 | .88 |
| aPLAs§ | ||||||||
| LA alone | 149 (20) | 42 (8) | 1.67 | 0.68-4.08 | .26 | 1.49 | 0.60-3.71 | .39 |
| LA + anti-β2GPI IgG/IgM | 149 (20) | 106 (12) | 0.64 | 0.26-1.56 | .32 | 0.70 | 0.28-1.76 | .46 |
| LA + anti-β2GPI IgG | 150 (20) | 83 (5) | 0.27 | 0.10-0.74 | .01 | 0.65 | 0.22-1.96 | .45 |
| LA + anti-β2GPI IgM | 149 (20) | 61 (10) | 1.41 | 0.59-3.39 | .44 | 1.17 | 0.47-2.92 | .74 |
| LA + aCL IgG/IgM | 151 (20) | 68 (6) | 0.48 | 0.18-1.26 | .14 | 0.76 | 0.27-2.17 | .61 |
| LA + aCL IgG | 151 (20) | 56 (4) | 0.35 | 0.12-1.05 | .06 | 0.68 | 0.21-2.21 | .52 |
| LA + aCL IgM | 151 (20) | 21 (3) | 1.22 | 0.36-4.15 | .76 | 1.29 | 0.36-4.64 | .69 |
| LA + anti-β2GPI + aCL (triple positivity) | 149 (20) | 66 (6) | 0.51 | 0.19-1.32 | .17 | 0.81 | 0.28-2.32 | .70 |
Predictors of survival have been calculated in the cohort of LA-positive individuals using univariable Cox-regression analysis with prospective thrombosis as a time-dependent variable and in multivariable analysis.
N1 represents the total number of patients; n1, the number of deaths in N1. N2 represents the number of patients with the respective characteristic; n2, the number of deaths in N2.
Multivariable analysis adjusted for age, hypertension, and TE during follow-up (variables “TE during follow-up,” “Hypertension at study inclusion,” and “Age at study inclusion” are adjusted only for each other).
Patients with at least 1 pregnancy (n = 95). Pregnancy complications were defined according to the current criteria.2,10
Cutoff: anti-β2GPI >8 GPL/MPL U/mL, aCL >40 GPL/MPL U/mL.